Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective ...

The growing prevalence of uterine fibroids, especially among women of reproductive age, is fueling the demand for treatment devices. This surge is fu ...

Patent lawyers are racing to adapt how they draft and defend drug-device patents after a court ruling reshaped the FDA’s ...

Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.

Phathom Pharmaceuticals, Inc. has secured 10 years of FDA exclusivity for Voquezna in GERD, boosting its stock. Click here to ...

Takeda Pharmaceutical Company Limited (NYSE: TAK )’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

Australian biotech TekCyte Limited appointed a new co-CEO leadership team consisting of Tony Simula, TekCyte’s founding CEO, as well as Tara James, a commercial strategist and founder of Small and ...

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Get Takeda Pharmaceutical alerts: Takeda Pharmaceutical (NYSE:TAK – Get Free Report ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. Healthcare, which includes numerous businesses that ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we ...